| An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients B Györffy, A Lanczky, AC Eklund, C Denkert, J Budczies, Q Li, Z Szallasi Breast cancer research and treatment 123, 725-731, 2010 | 2732 | 2010 |
| Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes G Von Minckwitz, M Untch, JU Blohmer, SD Costa, H Eidtmann, ... J Clin oncol 30 (15), 1796-1804, 2012 | 2509 | 2012 |
| The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014 R Salgado, C Denkert, S Demaria, N Sirtaine, F Klauschen, G Pruneri, ... Annals of oncology 26 (2), 259-271, 2015 | 2257 | 2015 |
| Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer C Denkert, S Loibl, A Noske, M Roller, BM Muller, M Komor, J Budczies, ... J Clin Oncol 28 (1), 105-113, 2010 | 1733 | 2010 |
| Pembrolizumab for early triple-negative breast cancer P Schmid, J Cortes, L Pusztai, H McArthur, S Kümmel, J Bergh, C Denkert, ... New England Journal of Medicine 382 (9), 810-821, 2020 | 1347 | 2020 |
| Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy C Denkert, G von Minckwitz, S Darb-Esfahani, B Lederer, BI Heppner, ... The lancet oncology 19 (1), 40-50, 2018 | 1312 | 2018 |
| Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial S Loi, S Michiels, R Salgado, N Sirtaine, V Jose, D Fumagalli, ... Annals of oncology 25 (8), 1544-1550, 2014 | 1226 | 2014 |
| De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 G Curigliano, HJ Burstein, EP Winer, M Gnant, P Dubsky, S Loibl, ... Annals of Oncology 28 (8), 1700-1712, 2017 | 1079 | 2017 |
| Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization J Budczies, F Klauschen, BV Sinn, B Győrffy, WD Schmitt, ... PloS one 7 (12), e51862, 2012 | 1047 | 2012 |
| Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial G Von Minckwitz, A Schneeweiss, S Loibl, C Salat, C Denkert, M Rezai, ... The lancet oncology 15 (7), 747-756, 2014 | 1003 | 2014 |
| Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative … C Denkert, G Von Minckwitz, JC Brase, BV Sinn, S Gade, R Kronenwett, ... J Clin oncol 33 (9), 983-991, 2015 | 986 | 2015 |
| Clinical relevance of host immunity in breast cancer: from TILs to the clinic P Savas, R Salgado, C Denkert, C Sotiriou, PK Darcy, MJ Smyth, S Loi Nature reviews Clinical oncology 13 (4), 228-241, 2016 | 709 | 2016 |
| Molecular alterations in triple-negative breast cancer—the road to new treatment strategies C Denkert, C Liedtke, A Tutt, G von Minckwitz The Lancet 389 (10087), 2430-2442, 2017 | 684 | 2017 |
| Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer G von Minckwitz, H Eidtmann, M Rezai, PA Fasching, H Tesch, ... New England Journal of Medicine 366 (4), 299-309, 2012 | 594 | 2012 |
| Assessing tumor infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the International Immuno-Oncology … S Hendry, R Salgado, T Gevaert, PA Russell, T John, B Thapa, M Christie, ... Advances in anatomic pathology 24 (6), 311, 2017 | 555 | 2017 |
| Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib … R Salgado, C Denkert, C Campbell, P Savas, P Nuciforo, C Aura, ... JAMA oncology 1 (4), 448-455, 2015 | 536 | 2015 |
| Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy W Weichert, A Röske, V Gekeler, T Beckers, C Stephan, K Jung, ... British journal of cancer 98 (3), 604-610, 2008 | 536 | 2008 |
| Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer M Kaufmann, G Von Minckwitz, EP Mamounas, D Cameron, LA Carey, ... Annals of surgical oncology 19, 1508-1516, 2012 | 534 | 2012 |
| Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers S Loi, D Drubay, S Adams, G Pruneri, PA Francis, M Lacroix-Triki, ... Journal of clinical oncology 37 (7), 559, 2019 | 523 | 2019 |
| Novel Theranostic Opportunities Offered by Characterization of Altered Membrane Lipid Metabolism in Breast Cancer ProgressionLipidomic Changes in Breast Cancer Progression M Hilvo, C Denkert, L Lehtinen, B Müller, S Brockmöller, ... Cancer research 71 (9), 3236-3245, 2011 | 515 | 2011 |
